INTRODUCTION
Successful regeneration after tissue injury requires timely coordinated actions of diverse cell types. In skeletal muscle, in response to acute damage, the muscle stem cell (satellite cell) progeny gives rise to new regenerating myofibers, aided by the concerted action of specialized cells, such as infiltrating bone-marrow-derived inflammatory cells, which phagocytose tissue debris and provide promyogenic growth factors and cytokines; fibrogenic stromal cells such as fibroblasts and adipogenic progenitors (FAPs), which provide transient matrix support; and angiogenic cells that vascularize the newly formed muscle tissue (Abou-Khalil et al., 2010; Mounier et al., 2011) . In chronically damaged muscle, however, this coordination is lost, leading to deficient regeneration . In the yet incurable Duchenne muscular dystrophy (DMD), caused by loss of the myofiber protein dystrophin, successive cycles of tissue degeneration and regeneration lead to an eventual muscle regenerative failure and replacement of dystrophic muscle by fibrotic tissue, resulting in respiratory failure and early death Stedman et al., 1991; Wallace and McNally, 2009) .
Cell plasticity (i.e., the capacity of cells to change their phenotypic properties) is inherent to organismal development and is becoming increasingly associated with tissue remodeling in the adult (Medici and Kalluri, 2012; Nieto, 2013) . Mesenchymal transitions (particularly epithelialand endothelial-to-mesenchymal transitions, EMTs and EndMTs, respectively) are connected both to fibrotic pathologies and cancer progression of distinct etiologies, affecting organs such as liver, lung, heart, or kidney (Medici and Kalluri, 2012; Nieto, 2013; Nieto and Cano, 2012; Zeisberg and Kalluri, 2013) . Lineage-tracing and fate-mapping strategies have precisely determined and quantified the source of fibrogenic cells in fibrotic kidney, underscoring the relevance of EMT, EndMT, and bone-marrow-derived cells to this organ's fibrosis (LeBleu et al., 2013) . Incomplete EMT also can occur in tumors, with cells acquiring mesenchymal properties without undergoing the full EMT as it also occurs in embryos, where intermediate phenotypes have been described in different contexts (Nieto, 2011 (Nieto, , 2013 Nieto and Cano, 2012) . These incomplete transitions implicate a change in cellular functions and behavior. In skeletal muscle, studies on cell plasticity during repair are emerging. In addition to resident interstitial fibroblasts and FAPs, which are considered the major producers of the collagen-rich extracellular matrix (ECM) in injured muscle and in young dystrophic muscle (Joe et al., 2010; Mann et al., 2011; Uezumi et al., 2011 Uezumi et al., , 2014 , perivascular progenitor cells transiently produce collagen in response to acute muscle damage, but disappear as regeneration advances (Dulauroy et al., 2012) . Similarly, depletion of macrophages or age-induced Wnt signaling in acutely injured muscle can divert vascular and myogenic cell fates, respectively (Brack et al., 2007; Zordan et al., 2014) . However, whether cell plasticity occurs in dystrophic muscle and how it affects disease progression have remained elusive.
Recently, fibrogenesis from muscle cells has been reported in DMD (Biressi et al., 2014 ).
Here we demonstrate that specialized cells of muscular, endothelial, and hematopoietic origins acquire mesenchymal-fibrogenic traits in dystrophic muscle, with this cellular plasticity being particularly associated with advanced DMD stages. The mesenchymal-fibrogenic plasticity of these cells is induced by increasing TGFb signaling in dystrophic muscle with aging, and results in the loss of cell identity, thus precluding normal regenerative functions. Together, our findings suggest that, during efficient tissue repair, specialized cells preserve their lineage identity by avoiding entrance into a mesenchymal-like/fibrogenic state. This protection is lost in chronic degenerative conditions such as DMD.
RESULTS
The levels of TGFb and downstream signaling mediators (activated SMAD2/3) increase in muscle of dystrophic mdx mice with age, correlating to reduced regeneration, angiogenesis and function, and higher fibrosis extent (Ardite et al., 2012; Kharraz et al., 2014; Mann et al., 2011; Vidal et al., 2008;  Figure 1A ; Figures S1A and S1B). Inflammatory cells and FAPs appeared as the principal sources of TGFb in dystrophic muscle ( Figure S1C ). Higher levels of this pathway also were found in muscle of wildtype (WT) mice after laceration (a severe injury model that induces persistent degeneration and more sustained fibrosis) than after cardiotoxin (CTX) injury (in which collagen-rich ECM is transient and full regeneration and muscle function are achieved rapidly) (Figures S1D and S1E) . In agreement with the profibrotic role of TGFb, exogenous delivery of TGFb to CTX-injured WT muscle or dystrophic muscle of young mdx mice delayed regeneration and vascularization, while promoting fibrogenesis. This suggests that TGFb inhibits myogenic and angiogenic capacity of muscle stem cell (satellite cell)-derived myoblasts and endothelial cells, respectively, while promoting matrix accumulation (Figures S1F and S1G) . Consistent with this, freshly isolated WT satellite cells were unable to fuse into myotubes in differentiation medium (DM) in the presence of TGFb ( Figure S2A ), correlating with gain of expression of fibrogenic genes (aSma, Collagen I, EdaFibronectin, or Timp1) and loss of myogenic gene expression (Myf5 and Pax7) after a 10-day treatment ( Figure S2B ). Likewise, endothelial cells isolated from skeletal muscle could not form angiotubes in vitro after a 10-day TGFb treatment period ( Figure S2C ), consistent with loss of expression of endothelial genes (Cd31 and Tie1) and de novo acquisition of fibrogenic traits ( Figure S2D ). These results indicate that TGFb induces the loss of identity of muscle-resident myogenic and endothelial cells by promoting their switch into matrix-producing fibrogenic cells, thus precluding their bona fide functions.
To further understand this cellular plasticity process induced by TGFb, we performed a microarray gene expression analysis of satellite cells treated (or not) with TGFb for 4 days (before achieving maximal levels of fibrogenic conversion, i.e., expression of aSma [ Figure S2B] ). Gene ontology functional annotation of genes upregulated in TGFb-treated myogenic cells, compared to non-treated cells, showed enrichment in mesenchymal-fibrogenic functions ( Figure S3A ). Moreover, after comparison with a curated list of mesenchymal progenitor cell-specific transcripts (Kubo et al., 2009 ), we identified a group of mesenchymal cell-specific genes induced by TGFb (Figure S3A) . qRT-PCR analysis of a TGFb cell-treatment kinetics experiment validated the expression of mesenchymal progenitor genes at intermediate time points (Figure 1B) . These mesenchymal genes were also significantly upregulated in endothelial cells isolated from skeletal muscle in response to identical TGFb treatment, prior to larger acquisition of fibrogenic traits ( Figure 1B ; see scheme in Figure 1C ).
To prove whether this gain of mesenchymal gene expression translated into de novo functional cellular multipotency (i.e., potential to differentiate into distinct cellular fates), satellite cells and endothelial cells were treated with TGFb for 3 days and further incubated with osteogenic or adipogenic medium for 7-14 days, or they continued to be treated with TGFb for 7 extra days. Notably, cells pretreated with TGFb showed induced expression of adipocyte, osteoblast, or fibrogenic traits under their respective differentiation regimes (Figures 1D and 1E ; Figure S3B ); in contrast, cells that had not been pretreated with TGFb did not undergo any of these conversions under identical differentiation conditions ( Figures 1D and 1E ). These results suggest that these two specialized cell types (myogenic and endothelial cells) gain expression of mesenchymal genes during the plastic process toward a more mature fibrogenic fate in response to TGFb; furthermore, these cells exhibit multipotency under adequate culture conditions (see scheme in Figure 1C ). Of note, TGFb was capable of inducing the expression of transcription factors and microRNAs associated with mesenchymal transitions in myogenic and endothelial cells ( Figures S3C and S3D ). In particular, Mir21 induction appeared to mediate TGFb-induced fibrogenesis in both cell types (Figure 2 ), reinforcing this Mir as a fibrogenic effector of TGFb action (Acuña et al., 2014; Ardite et al., 2012; Kumarswamy et al., 2012) .
Since TGFb levels and signaling are elevated in aged dystrophic muscle ( Figure 1A ), we next investigated whether endothelial and satellite cells also undergo plastic fibrogenesis in vivo. To this end, we generated endothelial Figure 1 . Increased TGFb Signaling at Advanced Muscular Dystrophy Stages and TGFb-Induced Cellular Plasticity (A) Active TGFb protein levels (ELISA) in limb muscles of mdx mice (C57BL/6 background) at distinct ages: young (2-3 months), adult (6-10 months), and old (18-24 months). Data correspond to the mean ± SEM values; n = 10 for each group. Non-parametric Mann-Whitney U test was used for comparison. Representative pictures of phosphorylated SMAD2/3 (P-SMAD2/3) protein immunostaining in mdx muscles are shown. *P-Smad2/3-positive cells. Scale bar, 50 mm.
(legend continued on next page) and satellite cell-lineage-tracing mice in two mdx dystrophic backgrounds, DBA/2 and C57BL/6, which develop substantial fibrosis in limb muscles at adult (6-10 months) or old (after 18 months) age, respectively Figures S4A and S4B Figure 3D ), supporting the occurrence of cell plasticity characterized by the reduction of endothelial identity traits and acquisition of the fibrogenic gene program, at advanced muscular dystrophy. This conclusion was confirmed by the detection of cells double positive for fibrogenic and endothelial cell markers in muscle at late dystrophic stages ( Figure S4C ; Figure 3E ), which coincided with the reduced vascularization and regeneration and increased fibrosis ( Figure S1B ). Furthermore, delivery of TGFb to CTX-injured muscle of Ve-CadCre ER /YFP mice induced the presence of YFP + CD31
low/À fibrogenic cells ( Figure 3F ), although to a lesser extent than in dystrophic muscle (Figures 3A and 3B) . qRT-PCR and immunofluorescence analysis confirmed the reduction of endothelial cell markers and gain of fibrogenic ones in the YFP + /CD31 low/À -sorted cells in TGFb/CTX-injured WT muscles ( Figures S4D and S4E ). Next, using a similar lineage-tracing strategy, we generated Pax7-Cre/YFP double-transgenic mice (obtained by intercrossing Pax7-Cre and Rosa26R-YFP mice, in which the expression of Cre is induced in Pax7-expressing muscle precursor cells) that were intercrossed with mdx/C57BL/6 dystrophic mice, and the resulting Pax7-Cre/YFP/mdx triple-mutant mice were aged up to 18-24 months. We also used Pax7-Cre ER /YFP mice (in which Cre is induced only in adult satellite cells upon tamoxifen administration) that were intercrossed with mdx/DBA/2 mice, generating Pax7-Cre ER /YFP/mdx triple-mutant mice, which were aged until advanced fibrogenic stages at adult age (6-10 months). Double-labeling cell sorting for YFP and the satellite cell marker a7-INTEGRIN allowed us to discriminate between bona fide satellite cells (YFP + a7 high )
and cells that had reduced or lost (YFP + a7 low/À ) a7-INTEGRIN expression after CTX/TGFb injury and in aged dystrophic mice. The YFP + a7 low/À cell population was induced specifically in CTX/TGFb-injured muscle (compared to CTX-injured, or non-injured, muscle) of Pax7-Cre ER /YFP mice ( Figure 4A ). This population was further increased (up to 11%-15%) in Pax7-Cre ER /YFP/mdx muscle of adult age (BDA/2 background) or old age (C57BL/6 background) ( Figure 4B ; Figure S4F ). Supporting the decline in myoblast cell identity in vivo, the expression of Pax7 decreased, while fibroblastic gene transcripts increased in YFP + a7 low/À cells from mdx and TGFb/injured WT muscles (Figures 4C and 4D) . Furthermore, in myofiber explants, the number of bona fide satellite cells associated with each myofiber decreased in fibrotic Pax7-Cre/YFP/mdx mice, as indicated by the lower number of YFP + cells expressing PAX7 or MYOGENIN (markers of quiescent/proliferating or differentiated myogenic cells, respectively), compared to age-matched WT myofibers ( Figure 4E ). Conversely, YFP + cells in mdx myofiber explants gained expression of fibrogenic markers ( Figure 4E ). Co-expression of fibrogenic and myogenic proteins (or YFP) ( Figure S4G ; Figure 4F ) further supported satellite cell fibrogenic plasticity in aged dystrophic muscle. Together, based on quantifications of these analyses (Figures 4B and 4E; Figure S4F ), 11.7% of cells of myogenic origin gained fibrogenic traits in aged dystrophic muscle. We subsequently tested the functional consequences of this fibrogenic plasticity in dystrophic muscle. The fluorescence-activated cell sorting (FACS)-isolated cells of endothelial and myogenic origins (YFP + ) that had reduced
) showed a severely impaired capacity to form angiotubes and myotubes in pro-angiogenic Figure S1F ) and quantification of YFP + cells that have reduced/lost a7-integrin expression. Values are mean ± SEM; n = 6 animals for each group. Nonparametric Mann-Whitney U test was used for comparison.
(legend continued on next page) and pro-myogenic differentiation conditions, respectively ( Figure 4G ). Despite the significant fraction of both endothelial and myogenic cells undergoing fibrogenic plasticity in dystrophic muscle, surprisingly, each cell type only constituted about 2% of the bona fide active collagen-expressing cell population (i.e., active fibroblasts), based on intracellular collagen protein staining of the YFP + CD31
low/À and YFP + a7 low/À cell populations, respectively ( Figure S5A) . Similarly, using a ColI-GFP reporter mice (in which GFP expression is under the control of the Collagen I promoter), only a low percentage of CD31 + and a7-INTEGRIN + cells were found within the fibroblastic (GFP + ) cell population ( Figure S5B ). These findings strongly suggest that, unlike other fibrotic organs, such as kidney (LeBleu et al., 2013) , these fibrogenic changes do not lead to full and ample transformation into collagen-producing cells. Instead, this fibrogenic plasticity mainly precludes efficient myogenesis and angiogenesis and it impairs tissue repair.
We next investigated if endothelial and satellite cells also transit through intermediate mesenchymal progenitor states during the process of fibrogenesis in diseased muscle. To this end, we set up a FACS protocol based on the use of the cell surface mesenchymal progenitor marker PDGFRa (Chong et al., 2013; Pinho et al., 2013; Uezumi et al., 2010 Uezumi et al., , 2014 Figure 5C ). Thus, during the process of endothelial and satellite cell plasticity toward fibrogenesis, a fraction of cells shows mesenchymal progenitor traits. This was consistent with a subpopulation of YFP + endothelial or myogenic cells also gaining PDGFRa + expression in WT muscle subjected to CTX/TGFb injury ( Figure 5D ). Consistent with the notion that TGFb signaling is a driving cause for these plastic mesenchymal transitions, we could detect co-expression of activated SMAD2/3 in PDGFRa + /YFP + cells in muscle of the distinct lineage-tracing mice (in various muscle degeneration/ fibrosis paradigms) ( Figure 5E ; Figure S5D ; data not shown) and in human DMD (see below). Figure 1) , involves multipotent progenitor cell intermediate states. Of note, in vivo interference with PDGFRa signaling with imatinib (a tyrosine kinase inhibitor), which has been shown to target PDGFRa-expressing mesenchymal progenitor cells (Ito et al., 2013; Uezumi et al., 2014) , prevented the loss of cell identity in injured muscle in response to TGFb ( Figure S5E ).
Mesenchymal cells in the bone marrow are multipotent in nature. Since fibrocytes (defined as bone-marrowderived cells expressing the hematopoietic marker Cd45 and Collagen I) contribute to fibrosis in organs such as kidney, liver, lung, and heart (Duffield et al., 2013; Kisseleva and Brenner, 2012; Krenning et al., 2010) , we hypothesized that fibrocytes also could contribute to fibroblast heterogeneity and fibrosis in dystrophic muscle. To test this possibility, we transplanted bone marrow from ColI-GFP reporter mice into young (3-month-old) mdx/C57BL/6 mice, and the transplanted mice were aged for fibrosis development for 18 extra months. A significantly increased number of GFP + cells was found in the muscle of transplanted dystrophic mice of 22 months of age (as an indication of collagen-producing cells derived from the donor bone marrow) compared to muscle of similarly transplanted non-dystrophic mice ( Figure 5H ). Consistent with this, compared to GFP + cells from transplanted WT muscles, the FACS-isolated GFP + cell population in aged dystrophic muscle showed reduced expression of the Cd45 hematopoietic cell marker, while the expression of fibrogenic markers increased ( Figure 5I ), and this was in agreement with the detection of cells co-expressing fibrogenic and hematopoietic markers in advanced muscle disease stages ( Figure S5F ). As for endothelial and satellite cells, only 2%-3% of fibrocytes appeared to contribute to the overall population of collagen-expressing cells in dystrophic muscle ( Figures S5A and S5B ). Together, these results demonstrate the acquisition of fibrogenic traits by hematopoietic cells at advanced fibrotic states of muscular dystrophy, and further illustrate the existence of mesenchymal plasticity of distinct specialized cells in dystrophic muscle, with deleterious consequences on disease progression.
As in dystrophic mice, we found that fibrosis was specifically induced in muscles of human DMD patients (compared to healthy individuals), being more prominent in affected patients between 6 and 8 years of age than in younger 2-to 4-year-old children ( Figure 6A ), and this correlated with disease severity and physical incapacitation (not shown). We also detected fibrogenic (TCF4 + ) cells in fibrotic muscle of DMD patients that increased with age ( Figure 6A ). In DMD muscles, we also identified fibrogenic cells co-expressing vWF (a marker of endothelial cells), CD56 (a marker of human satellite cells), and CD45 (a hematopoietic marker) ( Figure 6B ), demonstrating cell plasticity in the human pathology, as in mdx dystrophic mice ( Figures S4C, S4G , and S5F; Figures 3, 4, and 5). Because active TGFb levels and signaling (P-SMAD2/3) also were increased in human DMD muscles, as fibrosis and disease severity progressed with age ( Figure 6C ), and because activated SMAD2/3 was specifically associated with cells expressing markers of fibrogenic and specialized cells in human and murine dystrophic muscle (Figures 6C  and 6D ; Figure S5D ), these results, taken together, reinforce the idea of TGFb being a plasticity-promoting factor in DMD. Consistent with this, DMD muscles contained cells expressing the mesenchymal progenitor cell marker PDGFRa together with markers of endothelial, myogenic, and hematopoietic cells, respectively ( Figure 6E ), and PDGFRa-expressing cells that were double positive for P-SMAD2/3 and TCF4 ( Figure 6D ). Thus, in muscle of DMD patients, as in dystrophic mice, fibrogenic cells are a heterogeneous population, and part of these cells may arise from plastic events within the TGFb-enriched dystrophic milieu. Consistent herewith, human myoblasts also showed fibrogenic plasticity in vitro in response to TGFb treatment ( Figure 6F ). Moreover, in vivo inhibition of TGFb signaling, via the administration of LY2157299 (a specific inhibitor of the TGFb receptor type 1 kinase) (Zhou et al., 2011) in old dystrophic mdx mice, reduced the presence of collagen-producing cells co-expressing markers of the specialized lineages ( Figure 6G ), while reducing fibrosis and restoring dystrophic muscle regeneration and vascularization ( Figure 6G) . Altogether, these results unveil TGFb as a driver of fibrogenic cell plasticity both in human and mouse dystrophic and severely damaged muscle.
DISCUSSION
Our study provides insights into the mechanisms underlying the loss of regenerative potential and increasing fibrogenesis with age in DMD. We report that a proportion of specialized cells, which are critical for muscle regeneration, cannot maintain their identifying functions in aged dystrophic muscle of humans and mice, and acquire instead the capacity to produce matrix proteins. This is in agreement with a recent report from the Rando group (Biressi et al., 2014) . Fibrogenesis in dystrophic muscle does not appear to be an all-or-nothing but rather a partial transition, as most cells share original as well as new fibroblastic traits, resembling the partial EMTs occurring in carcinosarcomas and fibrotic liver (Nieto, 2013; Sarrió et al., 2008; Zeisberg et al., 2007) . This cellular plasticity, however, hampers muscle tissue repair potential. Mechanistically, we show that the loss of cell identity toward fibrogenesis in dystrophic muscle may involve the acquisition of mesenchymal traits, triggered by increasing TGFb as disease progresses. This link between skeletal muscle fibrogenesis and mesenchymal-like transitional states, resulting in the loss of regenerative potential, was a striking finding. Because adipose tissue also accumulates in muscle of DMD patients, we postulated that the loss of identity of specialized cells concomitantly with the acquisition of mesenchymal-like (multipotent) characteristics might be a general feature for fibrogenesis as for adipogenesis in DMD, and by extension in other pathological conditions coursing with high TGFb signaling and tissue damage. Indeed, TGFb2-or BMP4-induced EndMT into multipotent stem-like cells was proposed to be the origin of heterotopic cartilage and bone in individuals with fibrodysplasia ossificans progressiva (FOP) lesions (Medici et al., 2010) . A distinct muscleresident multipotent progenitor additionally was proposed as an origin for FOP, based on its osteogenic potential in response to BMP2 (Wosczyna et al., 2012) .
Recent studies have shown that, in addition to fibroblasts, tissue-resident FAPs and perivascular cells, which express PDGFRa, can differentiate to a fibroblastic fate and contribute to collagen accumulation in acutely injured muscle (Dulauroy et al., 2012; Joe et al., 2010; Uezumi et al., 2010) . FAPs also accumulate in young dystrophic muscle prior to maximal fibrosis (Uezumi et al., 2011) , being the main source of the fibrogenic progeny leading to collagen production at early dystrophy stages. Our results demonstrate that at advanced DMD stages there are additional reservoirs of fibrogenic cells derived from myogenic, endothelial, and hematopoietic cells. However, unlike organs like kidney, where a great proportion of the fibrotic cells arise from the bone marrow (and to a lesser extent from EndMT or EMT) (LeBleu et al., 2013) , in dystrophic skeletal muscle, the net contribution of these cells to the actual population of collagen-producing cells (the key cells for fibrosis development) is modest. Instead, our results reveal that it is the loss of myogenic and endothelial cells' biochemical and phenotypic identities, through plastic mesenchymal transitions (characterized by the expression of PDGFRa), that causes severe deficits in myogenesis and angiogenesis, thus exacerbating the regenerative impairment in dystrophic muscle (see scheme in Figure 1 ). Therapeutically, a unifying model of loss of cell (B) Representative picture of co-staining of TCF4 with endothelial, myogenic, and hematopoietic cell markers, respectively, in DMD muscles. Nuclei are stained with DAPI. (C) Representative picture of P-SMAD2/3 staining and active TGFb protein levels in muscle biopsies from healthy individuals and DMD patients 6-8 years of age. Data correspond to the mean ± SEM; n = 10 in each group. Non-parametric Mann-Whitney U test was used for comparison.
(D) Representative immunostaining shows human cell co-expressing PDGFRa and P-SMAD2/3 or TCF4 in DMD muscle.
(E) Representative immunostaining shows human cells expressing PDGFRa and vWF, PAX7, or CD45 in DMD muscle. Nuclei are stained with DAPI. (F) Human myoblasts were treated with TGFb or vehicle for 6 days and analyzed for the expression of the indicated genes. Values are mean ± SEM; n = 3 independent experiments for each group. Unpaired t test was used for comparison. (G) Reduction of GFP + cells co-expressing CD31, a7-INTEGRIN, or CD45 in adult ColI-GFP/mdx muscle after treatment with the TGFb signaling inhibitor LY2157299 (or vehicle) for 1 month. Quantification shows fibrosis reduction and increased regeneration and vascularization. Data correspond to the mean ± SEM; n = 3 for each group. Non-parametric Mann-Whitney U test was used for comparison. Scale bars, 50 mm. fate and acquisition of mesenchymal traits centered on the PDGFRa-expressing cell could be envisioned. How to restrict deleterious PDGFRa-dependent functions while preserving the beneficial ones is likely to be more challenging.
Our findings support the notion that, in chronic degenerative conditions, the ability of specialized cells (such as myogenic, endothelial, and inflammatory cells) to undergo mesenchymal transitions is inversely correlated to the degree of tissue regeneration, while facilitating fibrogenesis. This has implications for regenerative medicine, as our findings unravel a physiological form of plasticity that can be co-opted toward disease-associated tissue degeneration and aging.
EXPERIMENTAL PROCEDURES

Mice
Mdx mice were maintained in C57BL/10 or DBA/2 backgrounds. Lineage-tracing mice have been described previously as follows: Cdh5-Cre ER , Tie2-Cre transgenic (Kisanuki et al., 2001 ), Pax7-Cre and Pax7-Cre ER (Nishijo et al., 2009 ), R26R-EYFP (Srinivas et al., 2001) , and Col1a1-3.6GFP (Coll-GFP) (Krempen et al., 1999) . Lineage-tracing mice were intercrossed with C57BL/10 or DBA/2 dystrophic mdx mice . When needed, Cre activity was induced by intraperitoneal injection (one injection per day for 4 days) with 5 mg/25 g body weight tamoxifen (TAM) (Sigma; 10 mg/ml in corn oil). Bone marrow transplantation experiments were performed as previously described , using Coll-GFP mice as bone marrow donor and mdx/C57BL/10 at 3 months of age as recipient mice; mice were aged for 18 months for fibrosis development.
Induction of Muscle Regeneration and Fibrosis
Regeneration of skeletal muscle was induced by intramuscular injection of 50 ml 10 À5 M CTX (Latoxan). Muscles were collected at the indicated times on each set of experiments, which was usually 2 weeks after myotoxin injection. Contralateral control muscles were left un-injured. To induce a more severe fibrotic injury, tibialis anterior (TA) muscles of WT mice were subjected to laceration as previously described (Ardite et al., 2012) . To exacerbate fibrotic muscle damage, 50 ng TGFb (recombinant TGFb1 and TGFb2, R&D Systems) was injected into previously injured (or dystrophic) TA and gastrocnemius muscle in a volume of 50 ml PBS, as previously described . For the inhibition of TGFb, LY2157299 (a specific inhibitor of the TGFb receptor type 1 kinase) (Zhou et al., 2011) was administered to old mdx mice (in the Coll-GFP background) for 30 days at a 25 mg/kg daily dose, and different parameters were analyzed thereafter. For the inhibition of PDGFRa signaling, imatinib (a tyrosine kinase inhibitor), which has been shown to target PDGFRa-expressing mesenchymal progenitor cells (Ito et al., 2013; Uezumi et al., 2014) , was administered to 7-day-CTX-injured mice for an additional 7-day period (50 mg/kg daily), coinciding with the administration of TGFb, and analyzed subsequently.
Cell Culture and Differentiation
Primary myoblasts were obtained from mouse skeletal muscle, grown in Ham's F10 medium (BioWest) supplemented with 20% fetal bovine serum (FBS) and basic fibroblast growth factor (bFGF, 0.025 mg ml À1 ), as described previously . Primary endothelial cells were grown in high-glucose DMEM (BioWest) supplemented with 10% FBS and 10 ng/ml vascular endothelial growth factor (VEGF), as described previously (Ieronimakis et al., 2008) . Human myoblasts were purchased from Cook Myosite and cultured following the provided instructions. When indicated, cells were treated with TGFb1 (myoblasts) or TGFb2 (endothelial cells) (10 ng/ml). To induce differentiation into distinct lineages, cells were grown in StemXVivo osteogenic and adipogenic culture media (R&D Systems), after 4 days of TGFb treatment. Alkaline phosphatase staining to detect osteoblasts was performed with the alkaline phosphatase kit (Sigma-Aldrich) on cultures grown in osteogenic medium for 14 days. Oil red O (Sigma-Aldrich) staining to detect adipocytes was performed on cultures grown in adipogenic medium for 14 days. Alternatively, for fibrogenic differentiation, cells were cultured in TGFb-containing medium for an additional 7-day period.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software using the nonparametric Mann-Whitney U test or unpaired t test for independent samples, with a confidence level of 95% being considered statistically significant. The results are expressed as mean ± SEM. The number of samples analyzed per group is detailed in each figure.
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